Elevated levels of neopterin and pentraxin 3 in patients with rheumatoid arthritis

Basit Öğe Kaydı
dc.contributor.authorEkin, Sabri
dc.contributor.authorSivrikaya, Abdullah
dc.contributor.authorAkdag, Turan
dc.contributor.authorYilmaz, Sema
dc.contributor.authorGulcemal, Semral
dc.date.accessioned2024-02-23T14:29:49Z
dc.date.available2024-02-23T14:29:49Z
dc.date.issued2021
dc.departmentNEÜen_US
dc.description.abstractObjectives: As a systemic inflammatory disease, rheu-matoid arthritis (RA) is the most common inflammatory arthritis in the population and there is no specific diag-nostic marker in laboratory tests. The purpose of the study was to determine whether serum neopterin and pentraxin 3 (PTX3) levels may be a marker of increased inflammation in RA patients. Materials and methods: The study were consist of 30 RA patients and 30 healthy controls who were admitted to the department of rheumatology. Blood specimens were taken from both group, and the levels of neopterin were analyzed by chromatography method (HPLC) and the PTX 3 levels were measured by enzyme-linked immunosorbent assay (ELISA). All data and demographic characteristics of par-ticipants were also recorded. Results: Serum neopterin and PTX 3 levels of the patient group (25.99 +/- 7.24 ng/mL and 4.19 +/- 1.01 ng/dL, respec-tively) was higher than the control group (9.55 +/- 0.74 ng/mL and 2.23 +/- 0.39 ng/dL, respectively). These results were remarkable significant (p<0.01). No statistically significant correlation was found between age-PTX 3, age-neopterin and PTX 3-neopterin parameters in the patient group. In the control group, a significant negative correlation was found between age and PTX 3 (p<0.05), and a positive correlation between neopterin and PTX 3. Conclusions: Consequently, the serum neopterin and PTX 3 levels were higher in RA patients as compared to the healthy individuals. Our study suggest that there is a relation between neopterin and PTX 3 levels with RA patients. These findings suggest that neopterin and PTX 3 are important markers in the monitoring of RA disease.en_US
dc.identifier.doi10.1515/hmbci-2021-0012
dc.identifier.endpage423en_US
dc.identifier.issn1868-1883
dc.identifier.issn1868-1891
dc.identifier.issue4en_US
dc.identifier.pmid34303320en_US
dc.identifier.scopus2-s2.0-85111595239en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage419en_US
dc.identifier.urihttps://doi.org/10.1515/hmbci-2021-0012
dc.identifier.urihttps://hdl.handle.net/20.500.12452/14857
dc.identifier.volume42en_US
dc.identifier.wosWOS:000731727700013en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWalter De Gruyter Gmbhen_US
dc.relation.ispartofHormone Molecular Biology And Clinical Investigationen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectInflammationen_US
dc.subjectNeopterinen_US
dc.subjectPentraxin 3en_US
dc.subjectRheumatoid Arthritisen_US
dc.titleElevated levels of neopterin and pentraxin 3 in patients with rheumatoid arthritisen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu